Skip to main content
Download PDF

RNA interference-mediated silencing of DNA methyltransferase 1 attenuates neuropathic pain by accelerating microglia M2 polarization

BMC Neurology volume 22, Article number: 376 (2022) Cite this article

Abstract

Background

DNA methyltransferase 1 (DNMT1) exerts imperative functions in neuropathic pain (NP). This study explored the action of RNA interference-mediated DNMT1 silencing in NP by regulating microglial M2 polarization.

Methods

NP rat models were established using chronic constriction injury (CCI) and highly aggressive proliferating immortalized (HAPI) microglia were treated with lipopolysaccharide (LPS) to induce microglia M1 polarization, followed by treatment of DNMT1 siRNA or si-DNMT1/oe-DNMT1, respectively. The pain threshold of CCI rats was assessed by determining mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL). Levels of inflammatory factors (TNF-α/IL-1β/IL-6/IL-10) and DNMT1 in rat L4-L6 spinal cord samples and HAPI cells were measured using ELISA, RT-qPCR, and Western blot. iNOS and Arg-1 mRNA levels were measured via RT-qPCR. DNMT1, M1 marker (iNOS), and M2 marker (Arg-1) levels in microglia of CCI rats were detected by immunofluorescence. Percentages of M1 microglia phenotype (CD16) and M2 microglia phenotype (CD206) were detected by flow cytometry. The phosphorylation of PI3K/Akt pathway-related proteins was determined by Western blot.

Results

CCI rats exhibited diminished MWT and TWL values, increased pro-inflammatory cytokines, and decreased anti-inflammatory cytokine IL-10. Additionally, DNMT1 was upregulated in CCI rat microglia. DNMT1 siRNA alleviated CCI-induced NP and facilitated M2 polarization of microglia in CCI rats. DNMT1 knockdown inhibited LPS-induced M1 polarization of HAPI cells and promoted M2 polarization by blocking the PI3K/Akt pathway, but DNMT1 overexpression inhibited the M1-to-M2 polarization of microglia.

Conclusion

RNA interference-mediated DNMT1 silencing accelerates microglia M2 polarization by impeding the PI3K/Akt pathway, thereby alleviating CCI-induced NP.

Peer Review reports

Introduction

Neuropathic pain (NP) is recently defined as pain resulting from a disease or lesion affecting the somatosensory nervous system by the International Association for the Study of Pain, afflicting approximately 10% of the total population [1, 2]. It is usually attributed to damage and pathological changes in the peripheral or central nervous system (CNS), manifested as abnormal pain, hyperalgesia, spontaneous pain, and paresthesia [3]. Additionally, the primary disease mainly includes nerve injury caused by trauma, autoimmune disorders, diabetes, cancer, infection, and chemotherapy [4]. Unfortunately, considerable patients are refractory to conventional medical treatment [5]. Due to the complexity of its etiology, the pathogenesis of NP has not been completely elucidated and has emerged as a challenging issue in clinical practice.

It is noteworthy that neuroinflammation exerts a vital role in NP development [6]. Microglia, as the main innate immune cell in the CNS, constitute an immunoprotective barrier against various injuries to the CNS [7]. Notably, microglia are considered primary mediators in neuroinflammation [8], affect brain development, maintain the neural environment, and respond to nerve injury and repair [9]. The activation of microglia is intensely linked with NP initiation [10], and inhibiting over-activated microglia can weaken NP, suggesting that microglia probably are potential therapeutic targets against NP [11]. Under stress conditions, microglia are activated and polarized into M1 or M2 types [12]. The M1 phenotype is featured by highly-upregulated inflammatory factors, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-12, and inducible nitric oxide synthase (iNOS), causing neuroinflammatory responses; and conversely, the M2 phenotype is marked by the molecular features of CD206 and arginase (Arg-1) and releases beneficial mediators, such as IL-10 and transforming growth factor-β, which exerts a neuroprotective role [12,13,14]. Intriguingly, the M2 polarization of microglia could mitigate Alzheimer’s disease-related NP [15]. Additionally, dihydromyricetin extenuates NP by inducing the shift from M1 to M2 polarization by potentiating the aldehyde dehydrogenase 2 (ALDH2) activity [16]. Botulinum toxin type A facilitates microglia M2 polarization by repressing the purinergic ligand-gated ion channel 7 receptor (P2X7R), thus inhibiting chronic constriction injury (CCI)-elicited NP [17]. The compelling evidence has indicated the involvement of microglia polarization in NP. Therefore, the polarization switching from M1 to M2 phenotype is a promising treatment strategy for NP.

DNA methylation is induced by DNA methyltransferases (DNMTs), including DNMT1, DNMT3a, and DNMT3b [18], in which DNMT1 is vital in numerous processes, such as methylation maintenance, chromatin stability, and gene regulation [19]. Aberrant DNA methylation is presumably highly involved in CCI-induced NP [20]. DNMT1 and DNMT3a contribute to NP onset by epigenetically suppressing Kcna2 in primary afferent neurons [21, 22]. DNMT1 is upregulated in the spared nerve injury-induced NP rat models [23], and inhibition of DNMT1 potentiates M2 polarization of microglia in Alzheimer’s disease (AD)-related NP [15]. DNMT inhibitors include genistein, 5-azacytidine (5-Aza), and N-phthalyl-L-tryptophan (RG108) [24,25,26]. Specifically, 5-Aza has an anti-inflammatory efficacy and can treat inflammatory lung injury [27]. Additionally, oral azacitidine (CC-486), a DNMT inhibitor, can be used to treat tumors [28]. However, DNMT inhibitors show certain limitations, such as the inherent cytotoxic effects of nucleoside DNMT inhibitors, and some DNMT inhibitors present low specificity and cannot directly block the active site of DNMT. Therefore, in this present study, we used genetic modulation to interfere with DNMT1 to explore its mechanism in NP.

Several signaling pathways, including the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, are critical for microglia activation and inflammation [29,30,31]. The activation of the PI3K/Akt pathway contributes to the release of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), as well as iNOS expression [32]. The blocking of the PI3K/Akt pathway mitigates lipopolysaccharide (LPS)-induced neuroinflammation and reduces the levels of inflammatory factors such as TNF-α and IL-6 [33].

On a separate note, the PI3K/Akt pathway is pivotal for the development and maintenance of NP [34]. The blockade of this pathway exerts a mitigating effect on NP caused by surgery [35], suppresses inflammatory responses [36], and ameliorates cognitive impairment in NP rats [37]. Furthermore, the PI3K/Akt pathway is activated in CCI rat models [38], which participates in the activation of microglia [39] and M2 polarization of microglia [40, 41]. JTC-801 prominently impedes the Akt activation and diminishes the expressions of inflammatory factors, thereby palliating mechanical allodynia in paclitaxel-elicited NP [42]. Hence, suppression of the PI3K/Akt pathway probably is a primary therapeutic target for NP. Additionally, prior research has documented the promotion effect of DNMT1 on PI3K/Akt pathway activation [43]. Nevertheless, more studies remain to be carried out on whether suppression of DNMT1 by RNA interference represses NP via the modulation of microglia M2 polarization by blocking the PI3K/Akt pathway. Herein, this present study probed into the action of DNMT1 siRNA in NP by regulating microglia M2 polarization, expecting to offer potential intervention therapeutic targets for NP treatment.

Materials and methods

Ethics statement

All animal experiments were approved by the Ethics Committee for Animal Care and Use of Weifang Traditional Chinese Medicine Hospital. Significant efforts were taken to minimize the number of animals and their suffering. All methods were performed under the relevant guidelines and ARRIVE guidelines.

Experimental animals

Specific pathogen-free Sprague–Dawley healthy male rats (8 weeks old, weighing 200–220 g) were provided by Charles River (License No. SCXK (Beijing) 2021–0006, Beijing, China). Rats were reared in a temperature-controlled (20–25 °C) environment under 12 h light–dark cycles, with free access to food and water.

Establishment of NP models

NP rat models were constructed through chronic constriction injury (CCI) [44]. Rats were firstly anesthetized with an intraperitoneal injection of 50 mg/kg of 2% sodium pentobarbital (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). Next, the sciatic nerve was exposed by blunt dissection [45], and then 4 loose knots were made around the nerve at a 1-mm interval from the proximal end of the spine to the bifurcation using the 4–0 chromic catgut. The ligatures were tightened until the presence of slight fibrillation in the operated limb, followed by suture using 4–0 sterile surgical sutures. The sciatic nerve of rats in the sham group was exposed for the same period, but not ligated.

Animal treatment and grouping

Total 32 rats were arbitrarily allocated into 4 groups (8 rats/group): sham group, CCI group, CCI + siRNA-Ctrl group, and CCI + siRNA-DNMT1 group. Previous studies have revealed that the lateral ventricular delivery of siRNA effectively silenced the expression of target genes in the brain, with a range of 50–80% [46, 47]. Before CCI modeling, the rat head was fixed with a stereotaxic instrument and a small 1-mm-diameter hole was drilled on the right side of the rat skull; next, the lateral ventricle of rats was injected with 2 μL normal saline containing 20 nM siRNA-Ctrl or DNMT1 siRNA at a rate of 0.5 μL/min and then the needle stayed for 5 min in the brain after injection to prevent leakage; finally, bone wax was used to seal the burr hole and the incision was sutured [14]. The sham and CCI groups received an equivalent amount of normal saline. On the 14th day after CCI induction, rats were euthanized by injecting pentobarbital sodium (50 mg/kg) under anesthesia, and L4–L6 spinal cord samples were isolated for subsequent analyses [12]. Thereafter, 4 rats were used for immunofluorescence and another 4 rats were used for tissue homogenate, followed by reverse transcription quantitative polymerase chain reaction (RT-qPCR), Western blot, and enzyme-linked immunosorbent assay (ELISA). All the above procedures were performed under deep anesthesia. Additionally, the construction and packaging of DNMT1 siRNA and its negative control (NC) siRNA-Ctrl were performed by GenePharma (Shanghai, China).

Determination of pain threshold

All rats were habituated to the environment prior to behavioral testing [44]. The mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) of rats were measured on days 0, 3, 7, and 14 after CCI induction [9]. The 0-day was considered the day before CCI induction. A series of Von Frey filaments (2, 4, 6, 8, 10, and 15 g) (North Coast Medical, San Jose, CA, USA) was utilized to determine MWT value [16]. A plantar algometer (Tes7370, Ugo Basile, Comerio, Italy) was used to measure TWL value on the plantar surface of rat paws.

Immunofluorescence staining

Rat L4-L6 spinal cord samples were fixed, dehydrated, and frozen in a -80 °C freezer, and cryosectioned at 8 μm thickness for subsequent studies. The removed sections were dried for 10 min and rinsed thrice with phosphate-buffered saline (PBS) for 10 min each. Sections were rinsed thrice for 10 min each after breaking the membranes with 0.5% Triton for 2 h. Following repair using citrate solution, sections were naturally cooled and then rinsed thrice for 10 min each. Subsequently, sections was blocked with 2% bovine serum albumin and incubated overnight with following primary antibodies: anti-ionized calcium-binding adaptor molecule-1 (Iba-1) (red; 1:100, ab283319, Abcam, Cambridge, UK), anti-DNMT1 (green; 1:250, ab188453, Abcam), anti-iNOS (green; 1:250, ab178945, ab283319, Abcam), anti-Arg-1 (green; 1:200, ab96183, Abcam) at 4 °C, followed by washing with 0.01 moL/L PBS. Afterwards, sections were reacted for 1 h with secondary antibody immunoglobulin G (IgG, 1:2000, ab205718, Abcam) at 37 °C under dark conditions, and then washed. Following staining the nuclei with Hoechst for 10 min, sections were rinsed five times for 10 min each. The expression and localization of DNMT1, iNOS, and Arg-1 in microglia were determined after mounting using glycerol, with Iba-1 as a marker of microglia.

Cell culture and transfection

Rat microglial cell line (highly aggressive proliferating immortalized, HAPI) provided by BeNa Culture Collection (Xinyang, Henan, China) was cultured in high-glucose Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA) in an incubator with 5% CO2 and 95% humidity.

Cells were allocated into the following 7 groups: control group, LPS group (treated with 100 ng/mL LPS for 24 h), LPS + si-NC group (transfected with si-NC for 24 h, followed by LPS treatment for 24 h), LPS + si-DNMT1 group (transfected with si-DNMT1 for 24 h, followed by LPS treatment for 24 h), LPS + oe-NC group (transfected with oe-NC for 24 h, followed by LPS treatment for 24 h), LPS + oe-DNMT1 group (transfected with oe-DNMT1 for 24 h, followed by LPS treatment for 24 h), and LPS + si-DNMT1 + IGF-1 group (based on the LPS + si-DNMT1 group, cells were treated with Akt activator (insulin-like growth factor 1, IGF-1, 100 ng/mL) for 1 h [48]. IGF-1 (Enzyme-linked Biotechnology, Shanghai, China), si-DNMT1, si-NC, oe-DNMT1, and oe-NC (all from GenePharma) were transfected into HAPI cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at 50 nM.

ELISA

Rat L4-L6 spinal cord samples or HAPI cells were lysed using radio-immunoprecipitation assay (RIPA) lysis buffer containing protease inhibitors (Solarbio, Beijing, China) and centrifuged (14,000 × g, 5 min) to obtain the supernatant. Subsequently, the levels of inflammatory factors TNF-α (ml002953), IL-1β (ml037361), IL-6 (ml064292), IL-10 (ml028497) in tissue homogenate or cell supernatant were measured using ELISA kits (Enzyme-linked Biotechnology).

RT-qPCR

Total RNA in L4-L6 spinal cord samples and HAPI cells was extracted using the TRIzol method (Invitrogen). The RNA concentration was detected utilizing NanoDrop spectrophotometer (Thermo Fisher Scientific) and total RNA was reverse-transcribed to cDNA using PrimeScript RT reagent kits (Takara, Dalian, Liaoning, China). PCR amplification reactions were conducted using Dy NAmo™ SYBR® Green qPCR kits (Finnzymes, Espoo, Finland) on a Bio-Rad CFX96 fluorescence qPCR instrument (ABI, Carlsbad, CA, USA). The reaction conditions were as follows: pre-denaturation at 95 °C for 10 min, and then 40 cycles of denaturation at 95 °C for 10 s, annealing at 60 °C for 20 s, and extension at 72 °C for 34 s. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) acted as the internal control and the data were analyzed using the 2−ΔΔCt method. The primer sequences are detailed in Table 1.

Table 1 Primer sequences of RT-qPCR
Full size table

Flow cytometry

The percentage of M1/M2 microglia phenotype was determined by evaluating the levels of their corresponding markers CD16 and CD206. Firstly, rat L4-L6 spinal cord samples were cut with scissors, detached with 0.15% trypsin, and repeatedly blown into single-cell suspension, followed by isolation of mononuclear cells by Percoll density gradient centrifugation. The mononuclear cells were then resuspended in PBS and stained with fluorescence-labeled CD16 (ab246222, Abcam) and CD206 antibodies (ab270647, Abcam) for 30 min at 4 °C in the dark. For cell culture samples, HAPI cells were collected, rinsed with PBS, adjusted to 1 × 106 cells/mL, and stained with the same CD16 (Abcam) and CD206 (Abcam) antibodies. Later, the percentages of CD16 and CD206 were measured by a FACSCalibur flow cytometer equipped with FlowJo software (version vX 0.7) (Beckman Coulter, Brea, CA, USA).

Western blot

RIPA lysis buffer (Beyotime, Shanghai, China) was utilized to lyse rat L4-L6 spinal cord samples or HAPI cells, and then the protein concentration was measured with bicinchoninic acid protein assay kits (Beyotime). Proteins were separated using 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and subsequently electrotransferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). Afterwards, 5% skim milk was configured using Tris-buffered saline Tween-20 (TBST), and then the PVDF membranes were put into milk, followed by shaking and blocking for 1 h at room temperature to block non-specific binding. Thereafter, membranes were incubated overnight at 4 °C with primary antibodies: anti-DNMT1 (1:1000, ab188453, Abcam), anti-PI3K (1:1000, ab32089, Abcam), anti-p-PI3K (1:1000, ab278545, Abcam), anti-Akt (1:500, ab8805, Abcam), and anti-p-Akt (1:1000, ab38449, Abcam). Following washing twice with TBST, membranes were reacted for 1 h with horseradish peroxidase-labeled goat anti-rabbit secondary antibody IgG (1:2000, ab48386, Abcam) at room temperature. They were then developed with enhanced chemiluminescence working solution (Millipore) and photographed. The density of protein bands was detected with Image J software (version 1.48, NIH, Bethesda, MD, USA), with β-actin as the internal reference.

Statistical analysis

All data were processed using SPSS 21.0 statistical software (IBM Corp, Armonk, NY, USA). Measurement data were represented as mean ± standard deviation (SD). Data between two groups were analyzed using the independent sample t-test or one-way repeated measures analysis of variance (ANOVA), with one-way ANOVA for comparisons among multiple groups. Tukey’s multiple comparisons test was conducted for the post hoc analysis. The p < 0.05 indicated statistical significance.

Results

DNMT1 was upregulated in microglia of CCI rats

Compelling evidence has revealed the regulation of DNMT1 in NP onset [21]. To estimate the role of DNMT1 in NP, we established rat models of NP by CCI and firstly assessed the pain threshold of CCI rats by measuring MWT and TWL. The results revealed that CCI rats presented lower values of MWT and TWL than the sham group (all p < 0.01) (Fig. 1A-B). Additionally, to further assess the neuroinflammation in CCI rats, we measured the levels of TNF-α, IL-1β, IL-6, and IL-10 using ELISA, which demonstrated that the CCI group exhibited prominently higher contents of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 and lower level of anti-inflammatory cytokine IL-10 than the sham group (all p < 0.01) (Fig. 1C). Next, we measured DNMT1 expression levels and noted remarkably upregulated DNMT1 mRNA and protein levels in the CCI group compared with the sham group (p < 0.01) (Fig. 1D-E). Thereafter, immunofluorescence was employed to detect the localization of DNMT1 in microglia, which revealed noticeably highly-expressed DNMT1 in the plasma membrane of activated microglia (p < 0.01) (Fig. 1F). Overall, DNMT1 was upregulated in the microglia of CCI rats.

Fig. 1
figure 1

DNMT1 was upregulated in microglia of CCI rats. Rat models of NP were established by CCI. A-B MWT and TWL values measured on days 0, 3, 7, and 14; C Levels of inflammatory factors TNF-α, IL-1β, IL-6, and IL-10 measured by ELISA; D Expression of DNMT1 mRNA determined by RT-qPCR; E Protein level of DNMT1 determined by Western blot; F Expression and localization of DNMT1 in microglia determined by immunofluorescence (Red, Iba-1; green, DNMT1). N = 4, data were presented as mean ± SD. One-way repeated measures ANOVA was used to analyze the data in panels A/B and the t-test was used to analyze the data in panels C/D/E//F. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

DNMT1 siRNA alleviated CCI-induced NP

With the purpose to investigate the action of DNMT1 in NP, CCI rats were injected with 2 μL normal saline containing 20 nM DNMT1 siRNA to interfere with DNMT1 expression. Firstly, RT-qPCR and Western blot assays unveiled that DNMT1 mRNA and protein levels were significantly reduced in the CCI + siRNA-DNMT1 group compared with the CCI + siRNA-Ctrl group (p < 0.01) (Fig. 2A-B), indicating the successful interference of DNMT1 expression. Subsequently, we observed that the CCI + siRNA-DNMT1 group had higher MWT and TWL than the CCI + siRNA-Ctrl group (all p < 0.01) (Fig. 2C-D). Finally, ELISA detection unraveled that the CCI + siRNA-DNMT1 group exhibited lower TNF-α, IL-1β, and IL-6 contents and higher IL-10 levels than the CCI + siRNA-Ctrl group (all p < 0.01) (Fig. 2E). The aforementioned results indicated the mitigating effect of RNA interference-mediated DNMT1 knockdown on CCI-induced NP.

Fig. 2
figure 2

DNMT1 siRNA alleviated CCI-induced NP. CCI rats were treated with DNMT1 siRNA. A Expression of DNMT1 mRNA determined by RT-qPCR; B Protein level of DNMT1 determined by Western blot; C-D Measurement of MWT and TWL; E Levels of TNF-α, IL-1β, IL-6, and IL-10 determined using ELISA. N = 4, data were expressed as mean ± SD. The t-test was adopted to analyze the data in panels A/B/E and one-way repeated measures ANOVA was adopted to analyze the data in panels C/D. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

DNMT1 siRNA promoted microglia M2 polarization in CCI rats

Subsequently, we detected the levels of M1 marker (iNOS) and M2 marker (Arg-1) in rats to investigate the effect of CCI induction and DNMT1 siRNA on M2 polarization of rat microglia by immunofluorescence. The results demonstrated that compared with the sham group, the CCI group had increased Iba-1+iNOS+ cells (p < 0.01), slightly elevated Iba-1+ Arg-1+ cells (p < 0.05), and clearly raised M1/M2 ratio (p < 0.01), while DNMT1 siRNA contributed to significantly decreased number of Iba-1+iNOS+ cells, increased Iba-1+ Arg-1+ cells, and diminished M1/M2 ratio (all p < 0.01) (Fig. 3A-E). In addition, we examined M1 microglial phenotype (CD16) and M2 microglia phenotype (CD206) using flow cytometry and observed that CCI induction significantly increased the proportion of M1 microglia (p < 0.01) but had no obvious effect on the percentage of M2 microglia (p > 0.05), and DNMT1 siRNA significantly diminished the proportion of M1 microglia and increased the percentage of M2 microglia, resulting in the decreased ratio of M1/M2 (all p < 0.01) (Fig. 3F-J). Altogether, CCI induction resulted in M1 polarization of rat microglia, while inhibition of DNMT1 facilitated M2 polarization of CCI rat microglia.

Fig. 3
figure 3

DNMT1 siRNA promoted microglia M2 polarization in CCI rats. A-D Expression and localization of iNOS and Arg-1 in microglia detected by immunofluorescence (red, Iba-1; green, iNOS and Arg-1); E Ratio of M1/M2 microglia; F-I Percentages of M1 microglia phenotype (CD16) and M2 microglia phenotype (CD206) detected using flow cytometry; J Ratio of M1/M2 microglia. N = 4, data were exhibited as mean ± SD. Data among multiple groups were analyzed by one-way ANOVA, followed by Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

The effects of DNMT1 knockdown and overexpression on M1/M2 polarization in LPS-induced HAPI microglia

To further elucidate the specific role of DNMT1 in regulating M1/M2 polarization of microglia, the LPS-induced HAPI cells were transfected with si-DNMT1 or oe-DNMT1. Firstly, RT-qPCR and Western blot showed that compared with the control group, DNMT1 mRNA and protein levels were remarkably elevated in the LPS group; after interfering with DNMT1 expression in HAPI cells, DNMT1 levels were prominently reduced, while the LPS + oe-DNMT1 group showed notably higher DNMT1 levels than the LPS oe-NC group (all p < 0.01) (Fig. 4A-B). Flow cytometry revealed that LPS treatment significantly increased the percentage of M1 microglia (CD16) and the ratio of M1/M2 microglia, and DNMT1 siRNA prominently exerted contrary effects (all p < 0.01); additionally, the percentage of M2 microglia showed no significant change upon LPS treatment, but increased in the LPS + si-DNMT1 group relative to the LPS + si-NC group (p < 0.01) (Fig. 4C-E). Moreover, RT-qPCR and ELISA illustrated that LPS resulted in significant increases in M1 markers (iNOS, TNF-α, IL-1β, and IL-6), indicating that LPS promoted microglia polarization to the M1 phenotype. After silencing of DNMT1, iNOS, TNF-α, and IL-6 levels were markedly decreased, while M2 markers (Arg-1 and IL-10) were increased (all p < 0.01) (Fig. 4F-G). In contrast, overexpression of DNMT1 exerted the opposite results (Fig. 4A-G). Briefly, DNMT1 interference facilitated the M1-to-M2 polarization of microglia, whereas DNMT1 overexpression suppressed this M1-to-M2 polarization.

Fig. 4
figure 4

DNMT1 siRNA prevented LPS-induced M1 polarization and accelerated M2 polarization in HAPI cells. A RT-qPCR determined the expression of DNMT1 mRNA in HAPI cells; B Western blot determined the protein level of DNMT1; C-D Flow cytometry detected the percentages of M1 microglia phenotype (CD16) and M2 microglia phenotype (CD206); E Ratio of M1/M2 microglia; F RT-qPCR measured the relative mRNA levels of iNOS and Arg-1; G ELISA determined the levels of TNF-α, IL-1β, IL-6, and IL-10. Cell experiment was conducted 3 times; data were shown as mean ± SD. Data among multiple groups were analyzed by one-way ANOVA, followed by Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

DNMT1 siRNA promoted microglia M2 polarization by blocking the PI3K/Akt pathway

To explore the downstream mechanism of DNMT1 siRNA in regulating M2 polarization of microglia, we treated LPS-induced HAPI cells with DNMT1 siRNA and Akt activator IGF-1. Western blot analysis unveiled that the LPS group had higher levels of p-PI3K/PI3K and p-Akt/Akt than the control group, DNMT1 siRNA significantly decreased p-PI3K/PI3K and p-Akt/Akt levels, while the LPS + si-DNMT1 + IGF-1 group exhibited higher p-PI3K/PI3K and p-Akt/Akt than the LPS + si-DNMT1 group (all p < 0.01) (Fig. 5A-C), indicating that DNMT1 siRNA inhibited LPS-stimulated PI3K/Akt pathway activation and IGF-1 activated the PI3K/Akt pathway. Subsequently, we explored the effect of the PI3K/Akt pathway on M2 polarization. Compared with the LPS + si-DNMT1 group, the LPS + si-DNMT1 IGF-1 group had a markedly increased percentage of M1 microglia, M1/M2 ratio, and M1 markers (iNOS, TNF-α, IL-1β, and IL-6), but diminished M2 microglia and M2 markers (Arg-1 and IL-10) (all p < 0.01) (Fig. 5D-J). In summary, DNMT1 siRNA facilitated microglia M2 polarization by impeding the PI3K/Akt pathway.

Fig. 5
figure 5

DNMT1 siRNA promoted microglia M2 polarization by blocking the PI3K/Akt pathway. A-C Protein levels of PI3K, p-PI3K, Akt, and p-Akt measured by Western blot. D-G M1 microglia phenotype (CD16) and M2 microglia phenotype (CD206) detected using flow cytometry; H Ratio of M1/M2 microglia; I The relative mRNA levels of iNOS and Arg-1 measured by RT-qPCR; J Levels of TNF-α, IL-1β, IL-6, and IL-10 determined by ELISA. Cell experiment was conducted 3 times; data were exhibited as mean ± SD. Data among multiple groups were analyzed by one-way ANOVA, followed by Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

Discussion

NP is a frequent clinical chronic pain, which also remains a refractory disease that causes a considerable burden on the somatic and mental health of patients [49, 50]. Transfer of microglia polarization from M1 to M2 phenotype is considered a prospective therapeutic strategy for NP [51]. Additionally, DNA methylation affects the development of NP and DNMT1 is a principle isoform of DNMTs to sustain DNA methylation in mammals [44]. The PI3K/Akt pathway is necessitated for NP progression and maintenance [52]. This study highlighted the function of DNMT1 silencing in NP via regulating microglia M2 polarization and PI3K/Akt pathway.

MWT and TWL are widely recorded to assess the mechanical hypersensitivity and thermal hyperalgesia [53], and lower MWT and TWL are indicative of successful CCI models [54]. Firstly, we successfully established NP rat models via CCI, as manifested by reduced MWT and TWL values. NP is commonly featured by neuroinflammation, and its pathogenesis involves the increased levels of pro-inflammatory cytokines (including TNF-α, IL-6, COX-2, and IL-1β) and decreased anti-inflammatory cytokines (such as IL-4 and IL-10) [55]. Hence, we detected the inflammation and found elevated TNF-α, IL-1β, and IL-6 levels, and decreased IL-10 in CCI rats as expected. TNF-α is imperative in regulating immediate and ongoing stages of NP and the administration of TNF-α or IL-6 evokes thermal hyperalgesia and mechanical allodynia in rats [56]. Due to the substantial involvement of DNMT1 in NP as existing research reported [57], we measured the expression of DNMT1 and noted an upregulated DNMT1 in activated microglia of CCI rats, which was similar to the findings of Sarah L et al. [23]. Furthermore, we administrated CCI rats with DNMT1 siRNA to explore the function of DNMT1 in NP. The results unveiled that DNMT1 siRNA enhanced MWT and TWL values and suppressed neuroinflammation in CCI rats. Preceding evidence has elicited that DNA methylation regulates inflammation by epigenetically mediating signal transduction molecules, including myeloid differentiation factor 88 (MyD88), tumor necrosis factor receptor-associated factor 6 (TRAF6), and Toll-like receptor 2 (TLR2) [58]. Interestingly, blockade of DNA methylation predominantly impacts pain behaviors during NP and inflammatory pain, and additionally, DNMT inhibitor reduces incision-induced mechanical hypersensitivity and thermal sensitivity and alleviates hind paw swelling and inflammation [59]. Meanwhile, DNMT1 in the injured dorsal root ganglia may be warranted for NP genesis and genetic knockdown or pharmacological suppression of DNMT1 extenuates nerve injury-elicited pain hypersensitivities; for instance, injection of RG108, a DNMT1 inhibitor, palliates spinal nerve ligation-evoked heat hyperalgesia, cold allodynia, and mechanical allodynia [21]. Taken together, DNMT1 siRNA could attenuate CCI-elicited NP.

Microglia activation and following inflammatory responses are paramount in NP advance and the transformation of microglia polarization to pro-inflammatory phenotype normally presents during neuroinflammation [60]. M1 polarization markers include iNOS and CD16, and M2 markers consist of Arg-1 and CD206 [61]. Hence, we detected the microglia M1 and M2 polarization. In CCI rats, we observed notably increased iNOS and M1 microglia, slightly raised Arg-1, but an elevated M1/M2 ratio. However, DNMT1 siRNA prominently diminished iNOS and M1 microglia, elevated Arg-1 and M2 microglia, and decreased M1/M2 ratio. Generally, following peripheral nerve damage, microglia in the adult spinal cord inclines to the M1 phenotype and over-generates pro-inflammatory mediators (such as IL-1β and TNF-α), which greatly sensitizes the spinal cord neurons and produces pain, and consequently, shifting from M1 to the M2 polarization of spinal cord microglia is effective in ameliorating NP [62]. Depletion of DNMT1 can alleviate AD-associated NP by inducing M2 polarization of microglia [15]. Briefly, CCI induction contributed to the M1 polarization of microglia, and DNMT1 siRNA promoted M2 polarization in CCI rats. We further elucidated the role of DNMT1 via in vitro experiments. HAPI cells were treated with LPS and transfected with si-DNMT1 or oe-DNMT1. The results were consistent with those in vivo studies. DNMT1 interference augmented the M1-to-M2 polarization of microglia, whereas DNMT1 overexpression exerted the opposite effects.

Preceding research has reported that the PI3K/Akt pathway, one of the most important microglial intracellular cascades, is implicated in NP [34] and microglia M2 polarization [40, 41]. Subsequently, we explored the downstream mechanism of DNMT1 siRNA in microglia M2 polarization. Based on our results, the phosphorylation of the PI3K/Akt pathway-related proteins was raised in LPS-treated HAPI cells but diminished upon treatment of DNMT1 siRNA. Furthermore, we noted that IGF-1 (the Akt activator) elevated M1 microglia and M1/M2 ratio and decreased M2 microglia. Consistently, CCI contributes to an increase in levels of p-PI3K and p-Akt, and inhibiting the PI3K/Akt pathway exerts anti-inflammatory responses, ultimately suppressing NP [36]. Furthermore, the PI3K/Akt pathway effectively regulates microglia polarization and LY294002, an Akt inhibitor, enhances M1 marker expression [63]. Previous research has demonstrated that DNMT1 could activate the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in diabetic retinopathy [64])and 3,6-dihydroxyflavone (3,6-DHF), an effective DNMT1 inhibitor, suppresses the PI3K/Akt/mTOR pathway in breast carcinogenesis [65]. Collectively, DNMT1 siRNA facilitated microglia M2 polarization by blocking the PI3K/Akt pathway.

In conclusion, this study demonstrated that RNA interference-mediated DNMT1 silencing mitigated NP via the promotion of microglia M2 polarization by impeding the PI3K/Akt pathway. However, this paper only preliminarily elicited the function of DNMT1 knockdown on the PI3K/Akt pathway, lacking in-depth studies. Additionally, we merely detected the markers of microglia M1 and M2 polarization at one time point. Future studies shall be conducted to figure out the action of DNMT1 knockdown in modulating M2 polarization of microglia at the molecular level, such as the downstream microRNAs of DNMT1. Meanwhile, changes in microglia M1 and M2 polarization markers at different time points can be detected.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

References

  1. Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53–9. https://doi.org/10.1097/j.pain.0000000000001365.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Finnerup NB, Kuner R, Jensen TS. Neuropathic Pain: From Mechanisms to Treatment. Physiol Rev. 2021;101(1):259–301. https://doi.org/10.1152/physrev.00045.2019.

    Article  CAS  PubMed  Google Scholar 

  3. Hu C, He M, Xu Q, Tian W. Advances With Non-coding RNAs in Neuropathic Pain. Front Neurosci. 2021;15:760936. https://doi.org/10.3389/fnins.2021.760936.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Xu S, Dong H, Zhao Y, Feng W. Differential Expression of Long Non-Coding RNAs and Their Role in Rodent Neuropathic Pain Models. J Pain Res. 2021;14:3935–50. https://doi.org/10.2147/JPR.S344339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Xu D, Ma X, Sun C, Han J, Zhou C, Chan MTV, et al. Emerging roles of circular RNAs in neuropathic pain. Cell Prolif. 2021;54(12):e13139. https://doi.org/10.1111/cpr.13139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lurie DI. An Integrative Approach to Neuroinflammation in Psychiatric disorders and Neuropathic Pain. J Exp Neurosci. 2018;12:1179069518793639. https://doi.org/10.1177/1179069518793639.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci. 2018;19(10):622–35. https://doi.org/10.1038/s41583-018-0057-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Suzumura A. Neuron-microglia interaction in neuroinflammation. Curr Protein Pept Sci. 2013;14(1):16–20. https://doi.org/10.2174/1389203711314010004.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang Y, Chen Q, Nai Y, Cao C. Suppression of miR-155 attenuates neuropathic pain by inducing an M1 to M2 switch in microglia. Folia Neuropathol. 2020;58(1):70–82. https://doi.org/10.5114/fn.2020.94008.

    Article  PubMed  Google Scholar 

  10. Zhao H, Alam A, Chen Q, A Eusman M, Pal A, Eguchi S, et al. The role of microglia in the pathobiology of neuropathic pain development: what do we know? Br J Anaesth. 2017;118(4):504–16. https://doi.org/10.1093/bja/aex006.

    Article  CAS  PubMed  Google Scholar 

  11. Inoue K, Tsuda M. Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nat Rev Neurosci. 2018;19(3):138–52. https://doi.org/10.1038/nrn.2018.2.

    Article  CAS  PubMed  Google Scholar 

  12. Jiang Y, Wang J, Li H, Xia L. IL-35 promotes microglial M2 polarization in a rat model of diabetic neuropathic pain. Arch Biochem Biophys. 2020;685:108330. https://doi.org/10.1016/j.abb.2020.108330.

    Article  CAS  PubMed  Google Scholar 

  13. Liu X, Ma J, Ding G, Gong Q, Wang Y, Yu H, et al. Microglia Polarization from M1 toward M2 Phenotype Is Promoted by Astragalus Polysaccharides Mediated through Inhibition of miR-155 in Experimental Autoimmune Encephalomyelitis. Oxid Med Cell Longev. 2021;2021:5753452. https://doi.org/10.1155/2021/5753452.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wu H, Zheng J, Xu S, Fang Y, Wu Y, Zeng J, et al. Mer regulates microglial/macrophage M1/M2 polarization and alleviates neuroinflammation following traumatic brain injury. J Neuroinflammation. 2021;18(1):2. https://doi.org/10.1186/s12974-020-02041-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jin J, Guo J, Cai H, Zhao C, Wang H, Liu Z, et al. M2-Like Microglia Polarization Attenuates Neuropathic Pain Associated with Alzheimer’s Disease. J Alzheimers Dis. 2020;76(4):1255–65. https://doi.org/10.3233/JAD-200099.

    Article  CAS  PubMed  Google Scholar 

  16. Zhang W, Yang L, Li L, Feng W. Dihydromyricetin attenuates neuropathic pain via enhancing the transition from M1 to M2 phenotype polarization by potentially elevating ALDH2 activity in vitro and vivo. Ann Transl Med. 2020;8(18):1151. https://doi.org/10.21037/atm-20-5838.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gui X, Wang H, Wu L, Tian S, Wang X, Zheng H, et al. Botulinum toxin type A promotes microglial M2 polarization and suppresses chronic constriction injury-induced neuropathic pain through the P2X7 receptor. Cell Biosci. 2020;10:45. https://doi.org/10.1186/s13578-020-00405-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Liu SY, Shan NN. DNA methylation plays an important role in immune thrombocytopenia. Int Immunopharmacol. 2020;83:106390. https://doi.org/10.1016/j.intimp.2020.106390.

    Article  CAS  PubMed  Google Scholar 

  19. Wang Y, Wang X, Zhang H, Han B, Ye Y, Zhang M, et al. Transforming Growth Factor-beta1 Promotes M1 Alveolar Macrophage Polarization in Acute Lung Injury by Up-Regulating DNMT1 to Mediate the microRNA-124/PELI1/IRF5 Axis. Front Cell Infect Microbiol. 2021;11:693981. https://doi.org/10.3389/fcimb.2021.693981.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wang Y, Lin ZP, Zheng HZ, Zhang S, Zhang ZL, Chen Y, et al. Abnormal DNA methylation in the lumbar spinal cord following chronic constriction injury in rats. Neurosci Lett. 2016;610:1–5. https://doi.org/10.1016/j.neulet.2015.10.048.

    Article  CAS  PubMed  Google Scholar 

  21. Sun L, Gu X, Pan Z, Guo X, Liu J, Atianjoh FE, et al. Contribution of DNMT1 to Neuropathic Pain Genesis Partially through Epigenetically Repressing Kcna2 in Primary Afferent Neurons. J Neurosci. 2019;39(33):6595–607. https://doi.org/10.1523/JNEUROSCI.0695-19.2019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhao JY, Liang L, Gu X, Li Z, Wu S, Sun L, et al. DNA methyltransferase DNMT3a contributes to neuropathic pain by repressing Kcna2 in primary afferent neurons. Nat Commun. 2017;8:14712. https://doi.org/10.1038/ncomms14712.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Pollema-Mays SL, Centeno MV, Apkarian AV, Martina M. Expression of DNA methyltransferases in adult dorsal root ganglia is cell-type specific and up regulated in a rodent model of neuropathic pain. Front Cell Neurosci. 2014;8:217. https://doi.org/10.3389/fncel.2014.00217.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Sharma M, Tollefsbol TO. Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition. Exp Cell Res. 2022;416(1):113160. https://doi.org/10.1016/j.yexcr.2022.113160.

    Article  CAS  PubMed  Google Scholar 

  25. Switzer CH, Cho HJ, Eykyn TR, Lavender P, Eaton P. NOS2 and S-nitrosothiol signaling induces DNA hypomethylation and LINE-1 retrotransposon expression. Proc Natl Acad Sci U S A. 2022;119(21):e2200022119. https://doi.org/10.1073/pnas.2200022119.

    Article  CAS  PubMed  Google Scholar 

  26. Zarei M, Shamaghdari B, Vahabi Z, Dalman A, Eftekhari YP. Epigenetic reprogramming in cloned mouse embryos following treatment with DNA methyltransferase and histone deacetylase inhibitors. Syst Biol Reprod Med. 2022;68(3):227–38. https://doi.org/10.1080/19396368.2022.2036868.

    Article  CAS  PubMed  Google Scholar 

  27. Lu CH, Chen CM, Ma J, Wu CJ, Chen LC, Kuo ML. DNA methyltransferase inhibitor alleviates bleomycin-induced pulmonary inflammation. Int Immunopharmacol. 2020;84:106542. https://doi.org/10.1016/j.intimp.2020.106542.

    Article  CAS  PubMed  Google Scholar 

  28. Gaillard SL, Zahurak M, Sharma A, Durham JN, Reiss KA, Sartorius-Mergenthaler S, et al. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Cancer. 2019;125(16):2837–45. https://doi.org/10.1002/cncr.32138.

    Article  CAS  PubMed  Google Scholar 

  29. Dong L, Li YZ, An HT, Wang YL, Chen SH, Qian YJ, et al. The E3 Ubiquitin Ligase c-Cbl Inhibits Microglia-Mediated CNS Inflammation by Regulating PI3K/Akt/NF-kappaB Pathway. CNS Neurosci Ther. 2016;22(8):661–9. https://doi.org/10.1111/cns.12557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yan Y, Liu Y, Yang Y, Ding Y, Sun X. Carnosol suppresses microglia cell inflammation and apoptosis through PI3K/AKT/mTOR signaling pathway. Immunopharmacol Immunotoxicol. 2022:1–11; doi: https://doi.org/10.1080/08923973.2022.2074448.

  31. Zheng K, Lv B, Wu L, Wang C, Xu H, Li X, et al. Protecting effect of emodin in experimental autoimmune encephalomyelitis mice by inhibiting microglia activation and inflammation via Myd88/PI3K/Akt/NF-kappaB signalling pathway. Bioengineered. 2022;13(4):9322–44. https://doi.org/10.1080/21655979.2022.2052671.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Cianciulli A, Calvello R, Porro C, Trotta T, Salvatore R, Panaro MA. PI3k/Akt signalling pathway plays a crucial role in the anti-inflammatory effects of curcumin in LPS-activated microglia. Int Immunopharmacol. 2016;36:282–90. https://doi.org/10.1016/j.intimp.2016.05.007.

    Article  CAS  PubMed  Google Scholar 

  33. Gao Y, Cui M, Zhong S, Feng C, Nwobodo AK, Chen B, et al. Dihydroartemisinin ameliorates LPS-induced neuroinflammation by inhibiting the PI3K/AKT pathway. Metab Brain Dis. 2020;35(4):661–72. https://doi.org/10.1007/s11011-020-00533-2.

    Article  CAS  PubMed  Google Scholar 

  34. Popiolek-Barczyk K, Mika J. Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain. Curr Med Chem. 2016;23(26):2908–28. https://doi.org/10.2174/0929867323666160607120124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Jiang Z, Chen Z, Chen Y, Jiao J, Wang Z. RETRACTED ARTICLE: Involvement of pro-inflammatory cytokines in diabetic neuropathic pain via central PI3K/Akt/mTOR signal pathway. Arch Physiol Biochem. 2021;127(6):I–IX. https://doi.org/10.1080/13813455.2019.1651869.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang W, Suo M, Yu G, Zhang M. Antinociceptive and anti-inflammatory effects of cryptotanshinone through PI3K/Akt signaling pathway in a rat model of neuropathic pain. Chem Biol Interact. 2019;305:127–33. https://doi.org/10.1016/j.cbi.2019.03.016.

    Article  CAS  PubMed  Google Scholar 

  37. Yuan L, Liu C, Wan Y, Yan H, Li T. Effect of HDAC2/Inpp5f on neuropathic pain and cognitive function through regulating PI3K/Akt/GSK-3beta signal pathway in rats with neuropathic pain. Exp Ther Med. 2019;18(1):678–84. https://doi.org/10.3892/etm.2019.7622.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Liu W, Lv Y, Ren F. PI3K/Akt Pathway is Required for Spinal Central Sensitization in Neuropathic Pain. Cell Mol Neurobiol. 2018;38(3):747–55. https://doi.org/10.1007/s10571-017-0541-x.

    Article  CAS  PubMed  Google Scholar 

  39. He GL, Luo Z, Shen TT, Wang ZZ, Li P, Luo X, et al. TREM2 Regulates Heat Acclimation-Induced Microglial M2 Polarization Involving the PI3K-Akt Pathway Following EMF Exposure. Front Cell Neurosci. 2019;13:591. https://doi.org/10.3389/fncel.2019.00591.

    Article  CAS  PubMed  Google Scholar 

  40. Yu Y, Luo X, Li C, Ding F, Wang M, Xie M, et al. Microglial Hv1 proton channels promote white matter injuries after chronic hypoperfusion in mice. J Neurochem. 2020;152(3):350–67. https://doi.org/10.1111/jnc.14925.

    Article  CAS  PubMed  Google Scholar 

  41. Peng J, Pang J, Huang L, Enkhjargal B, Zhang T, Mo J, et al. LRP1 activation attenuates white matter injury by modulating microglial polarization through Shc1/PI3K/Akt pathway after subarachnoid hemorrhage in rats. Redox Biol. 2019;21: 101121. https://doi.org/10.1016/j.redox.2019.101121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Huang J, Chen D, Yan F, Wu S, Kang S, Xing W, et al. JTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the PI3K/Akt pathway. Eur J Pharmacol. 2020;883:173306. https://doi.org/10.1016/j.ejphar.2020.173306.

    Article  CAS  PubMed  Google Scholar 

  43. Liu Y, Cheng H, Cheng C, Zheng F, Zhao Z, Chen Q, et al. ZNF191 alters DNA methylation and activates the PI3K-AKT pathway in hepatoma cells via transcriptional regulation of DNMT1. Cancer Med. 2022;11(5):1269–80. https://doi.org/10.1002/cam4.4535.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Liu K, Wu H, Gao R, Han G. DNA Methylation May be Involved in the Analgesic Effect of Hyperbaric Oxygen via Regulating FUNDC1. Pain Res Manag. 2020;2020:1528362. https://doi.org/10.1155/2020/1528362.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Zhu J, Yang J, Xu J. miR-223 Inhibits the Polarization and Recruitment of Macrophages via NLRP3/IL-1beta Pathway to Meliorate Neuropathic Pain. Pain Res Manag. 2021;2021:6674028. https://doi.org/10.1155/2021/6674028.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Nikolakopoulou AM, Montagne A, Kisler K, Dai Z, Wang Y, Huuskonen MT, et al. Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat Neurosci. 2019;22(7):1089–98. https://doi.org/10.1038/s41593-019-0434-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Godinho B, Henninger N, Bouley J, Alterman JF, Haraszti RA, Gilbert JW, et al. Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier. Mol Ther. 2018;26(11):2580–91. https://doi.org/10.1016/j.ymthe.2018.08.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Hu DX, Sun QF, Xu L, Lu HD, Zhang F, Li ZM, et al. Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma via the PI3K/AKT pathway. World J Gastroenterol. 2022;28(4):464–78. https://doi.org/10.3748/wjg.v28.i4.464.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Feng X, Niu L, Long M, Luo K, Huang X, Chen M, et al. Transcranial Ultrasound Stimulation of the Anterior Cingulate Cortex Reduces Neuropathic Pain in Mice. Evid Based Complement Alternat Med. 2021;2021:6510383. https://doi.org/10.1155/2021/6510383.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Tian MM, Li YX, Liu S, Zhu CH, Lan XB, Du J, et al. Glycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components. Molecules. 2021;27(1):255. https://doi.org/10.3390/molecules27010255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wang X, Jiang Y, Li J, Wang Y, Tian Y, Guo Q, et al. DUSP1 Promotes Microglial Polarization toward M2 Phenotype in the Medial Prefrontal Cortex of Neuropathic Pain Rats via Inhibition of MAPK Pathway. ACS Chem Neurosci. 2021;12(6):966–78. https://doi.org/10.1021/acschemneuro.0c00567.

    Article  CAS  PubMed  Google Scholar 

  52. Li X, Yang S, Wang L, Liu P, Zhao S, Li H, et al. Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1alpha pathway. J Pain Res. 2019;12:879–90. https://doi.org/10.2147/JPR.S185873.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Liu Y, Qin X, Lu X, Jiang J. Effects of inhibiting the PI3K/Akt/mTOR signaling pathway on the pain of sciatic endometriosis in a rat model. Can J Physiol Pharmacol. 2019;97(10):963–70. https://doi.org/10.1139/cjpp-2019-0156.

    Article  CAS  PubMed  Google Scholar 

  54. Li P, Wang YX, Yang G, Zheng ZC, Yu C. Sanguinarine Attenuates Neuropathic Pain in a Rat Model of Chronic Constriction Injury. Biomed Res Int. 2021;2021:3689829. https://doi.org/10.1155/2021/3689829.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Zhang Q, Zhou L, Xie H, Zhang H, Gao X. HAGLR aggravates neuropathic pain and promotes inflammatory response and apoptosis of lipopolysaccharide-treated SH-SY5Y cells by sequestering miR-182-5p from ATAT1 and activating NLRP3 inflammasome. Neurochem Int. 2021;145:105001. https://doi.org/10.1016/j.neuint.2021.105001.

    Article  CAS  PubMed  Google Scholar 

  56. Sakhaee MH, Sayyadi SAH, Sakhaee N, Sadeghnia HR, Hosseinzadeh H, Nourbakhsh F, et al. Cedrol protects against chronic constriction injury-induced neuropathic pain through inhibiting oxidative stress and inflammation. Metab Brain Dis. 2020;35(7):1119–26. https://doi.org/10.1007/s11011-020-00581-8.

    Article  CAS  PubMed  Google Scholar 

  57. Hsieh MC, Lai CY, Ho YC, Wang HH, Cheng JK, Chau YP, et al. Tet1-dependent epigenetic modification of BDNF expression in dorsal horn neurons mediates neuropathic pain in rats. Sci Rep. 2016;6:37411. https://doi.org/10.1038/srep37411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Meng R, Li D, Feng Z, Xu Q. MyD88 hypermethylation mediated by DNMT1 is associated with LTA-induced inflammatory response in human odontoblast-like cells. Cell Tissue Res. 2019;376(3):413–23. https://doi.org/10.1007/s00441-019-02993-0.

    Article  CAS  PubMed  Google Scholar 

  59. Sun Y, Sahbaie P, Liang D, Li W, Shi X, Kingery P, et al. DNA Methylation Modulates Nociceptive Sensitization after Incision. PLoS One. 2015;10(11):e0142046. https://doi.org/10.1371/journal.pone.0142046.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Zhou F, Wang X, Han B, Tang X, Liu R, Ji Q, et al. Short-chain fatty acids contribute to neuropathic pain via regulating microglia activation and polarization. Mol Pain. 2021;17:1744806921996520. https://doi.org/10.1177/1744806921996520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Guo Y, Gan X, Zhou H, Zhou H, Pu S, Long X, et al. Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation. Life Sci. 2020;263:118582. https://doi.org/10.1016/j.lfs.2020.118582.

    Article  CAS  PubMed  Google Scholar 

  62. Gong X, Chen Y, Fu B, Jiang J, Zhang M. Infant nerve injury induces delayed microglial polarization to the M1 phenotype, and exercise reduces delayed neuropathic pain by modulating microglial activity. Neuroscience. 2017;349:76–86. https://doi.org/10.1016/j.neuroscience.2017.02.051.

    Article  CAS  PubMed  Google Scholar 

  63. Shi X, Cai X, Di W, Li J, Xu X, Zhang A, et al. MFG-E8 Selectively Inhibited Abeta-Induced Microglial M1 Polarization via NF-kappaB and PI3K-Akt Pathways. Mol Neurobiol. 2017;54(10):7777–88. https://doi.org/10.1007/s12035-016-0255-y.

    Article  CAS  PubMed  Google Scholar 

  64. He Y, Dan Y, Gao X, Huang L, Lv H, Chen J. DNMT1-mediated lncRNA MEG3 methylation accelerates endothelial-mesenchymal transition in diabetic retinopathy through the PI3K/Akt/mTOR signaling pathway. Am J Physiol Endocrinol Metab. 2021;320(3):E598–608. https://doi.org/10.1152/ajpendo.00089.2020.

    Article  CAS  PubMed  Google Scholar 

  65. Peng X, Chang H, Gu Y, Chen J, Yi L, Xie Q, et al. 3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21. Cancer Prev Res (Phila). 2015;8(6):509–17. https://doi.org/10.1158/1940-6207.CAPR-14-0357.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by Weifang City Science and Technology Development Project (for Medicine)No.2019YX009.

Author information

Authors and Affiliations

  1. Department of Spinal Surgery, Weifang Traditional Chinese Medicine Hospital, No.1055, Weizhou Road, Kuiwen District, Weifang, 261041, China

    Ying Tan, Tao Liu, Peng Gao, Shitao Xu & Lei Tan

  2. Department of Spinal Surgery, Sunshine Union Hospital, Weifang, 261041, China

    Zongjiang Wang

Authors
  1. Ying Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zongjiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peng Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shitao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LT is the guarantor of integrity of the entire study; YT is responsible for study concepts, study design, and manuscript review; ZJW is responsible for literature research, experimental studies, and statistical analysis; TL, PG, and STX are responsible for clinical studies; TL is responsible for data acquisition, manuscript preparation; TL and PG are responsible for data analysis; YT and ZJW are responsible for manuscript editing; All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Ying Tan or Lei Tan.

Ethics declarations

Ethics approval and consent to participate

All animal experiments were approved by the Ethics Committee for Animal Care and Use of Weifang Traditional Chinese Medicine Hospital. Significant efforts were taken to minimize the number of animals and their suffering. All methods were performed under the relevant guidelines and ARRIVE guidelines.

Consent for publication

Not applicable.

Competing interests

All authors declare that there is no conflict of interests in this study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, Y., Wang, Z., Liu, T. et al. RNA interference-mediated silencing of DNA methyltransferase 1 attenuates neuropathic pain by accelerating microglia M2 polarization. BMC Neurol 22, 376 (2022). https://doi.org/10.1186/s12883-022-02860-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12883-022-02860-6

Keywords

BMC Neurology

ISSN: 1471-2377

Contact us